Inhalation

INH0426

Issue link: https://www.e-digitaleditions.com/i/1544305

Contents of this Issue

Navigation

Page 11 of 47

News about companies that support development of orally inhaled and nasal drug products (OINDPs), including regulatory approvals, new partnerships, new products and services, and results of clinical studies. 10 April 2026 Inhalation to quickly monitor individual can- ister leakage, rejecting those that fail pre- determined leakage val- ues. Utilizing the enhanced ferrule and unique inspection system can avoid lengthy batch storage, man- ual inspection and potential batch rejection that may be experienced with current weight loss meth- ods. e engineering design firm focuses on product and packaging design, and its principal engineers have more than 25 patents. DFE Pharma introduces data-verified CO 2 reduction to lactose portfolio GOCH, GERMANY—DFE Pharma announced the introduc- tion of EcoLact ® 2030, an initiative to provide pharmaceutical manu- facturers access to auditable CO 2 data and full value-chain traceabil- ity, enabling them to demonstrate Scope 3 emission reductions with- out operational disruption. A com- pany news release explained that pharmaceutical companies can face increasing pressure to meet current climate and environmental, social and governance (ESG) targets, par- ticularly when addressing Scope 3 emissions (all indirect emissions, except for purchased energy, that occur in the value chain). ose are often very difficult to quantify due to limited transparency and incon- sistent data quality. EcoLact 2030 can addresses this gap by providing primary, traceable emission data of an accelerated 30% CO 2 reduction across DFE Pharma's lactose port- folio, without relying on offsets or estimates. e release also noted that DFE Pharma's lactose excip- ients verified with EcoLact 2030 will remain unchanged in terms of quality, performance and regu- latory compliance, so manufactur- ers can achieve their sustainability goals without additional product requalification steps. continued on page 41 Drug, and Cosmetic (FD&C) Act. is makes the company eli- gible for 180 days of CGT exclu- sivity upon commercialization. Orbia creates Type IV DMF for Zephex ® 152a RUNCORN, UNITED KING- DOM—Orbia Fluor & Energy Materials announced it has estab- lished a US Type IV Drug Master File (DMF) for Zephex ® 152a, its next generation, low global warm- ing potential (low GWP) propel- lant for pressurized metered dose inhalers (pMDIs). As required for excipients, this creates a complete, ready-to-use, FDA-formatted data package that pharmaceutical com- panies can reference directly in their submissions to the US Food and Drug Administration (FDA). e DMF provides FDA review- ers with direct access to detailed information describing how the propellant is manufactured, con- trolled and tested in accordance with FDA requirements, without requiring companies to recreate or resubmit the same technical data. e DMF can be used from early development through com- mercialization. A company news release described potential benefits of the DMF, including reduction of regulatory risk, limited repeti- tion in technical work and support for more efficient FDA reviews, which could shorten review time- lines for companies transitioning existing inhalers or developing new pMDIs using next genera- tion, lower-GWP propellants. MKON granted US patent for enhanced pMDI ferrule RO U N D RO C K , T E X A S , UNITED STATES—MKON, LLC announced that a United States patent for an enhanced ferrule for pressurized metered dose inhalers (pMDIs) has been awarded to company principal Simon Freed. e patented design reduces ferrule material weight while offering the ability to use specialized inspection equipment INDUSTRY NEWS Glenmark launches first nebulized triple therapy for COPD MUMBAI, INDIA— Glenmark Pha rmac eut ic a l s a n nou nc ed the launch of Nebzmart ® GFB Smartules ® and Glenmark Airz ® FB Smartules ® , which they indi- cate are the world's first nebulized, fixed-dose triple therapy for the treatment of chronic obstructive pulmonary disease (COPD). Both products combine glycopyrro- nium, formoterol and budesonide to reduce airway obstruction and inflammation and improve lung function and symptom control. A company news release stated that "as a single, easy-to-use, nebulized therapy, it minimizes the burden of multiple medications." In a clinical study conducted in India, the neb- ulized triple therapy demonstrated rapid improvement in lung func- tion and better control of breath- lessness (dyspnea) among patients. Glenmark Specialty receives FDA approval for generic fluticasone propionate inhalation aerosol ELMWOOD PARK, NEW JER- SEY, UNITED STATES—Glen- mark Specialty has received final approval from the United States Food and Drug Administration (FDA) for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation. A company news release indicated the product has been determined by the FDA to be bioequivalent and therapeu- tically equivalent to the refer- ence listed drug (RLD), FloVent ® HFA Inhalation Aerosol, 44 mcg (GlaxoSmithKline, London, UK). Glenmark has also been granted a competitive generic therapy (CGT) designation for Flutica- sone Propionate Inhalation Aero- sol USP, 44 mcg per actuation and is the "first approved appli- cant" as defined in section 505(j) (5)(B)(v)(III) of the US Food,

Articles in this issue

view archives of Inhalation - INH0426